ARVN ▲ +4.5% - Arvinas, Inc.
$ARVN - Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting
04-NOV-2026 04:01 PM ET
Share this post
More filings for $ARVN
ARVN ▼ -0.7% - Arvinas, Inc.Nov 3, 2026ARVN ▲ +2.3% - Arvinas, Inc.Oct 27, 2026ARVN ▼ -1.1% - Arvinas, Inc.Oct 27, 2026ARVN ▲ +2.9% - Arvinas, Inc.Oct 7, 2026ARVN ▼ -4.0% - Arvinas, Inc.Oct 1, 2026ARVN ▼ -0.1% - Arvinas, Inc.Sep 29, 2026
View full $ARVN filing history →💬 Comments
Loading comments…
Leave a comment